SV2003001515A - Hidrato estable de un antagonista de receptores muscarinicos. pc22018 - Google Patents

Hidrato estable de un antagonista de receptores muscarinicos. pc22018

Info

Publication number
SV2003001515A
SV2003001515A SV2003001515A SV2003001515A SV2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A
Authority
SV
El Salvador
Prior art keywords
synthro
urbanity
bladder
antagonist
muscarinic receptors
Prior art date
Application number
SV2003001515A
Other languages
English (en)
Spanish (es)
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Connor Garry O
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2003001515(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SV2003001515A publication Critical patent/SV2003001515A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SV2003001515A 2002-03-26 2003-03-25 Hidrato estable de un antagonista de receptores muscarinicos. pc22018 SV2003001515A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
SV2003001515A true SV2003001515A (es) 2003-12-15

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001515A SV2003001515A (es) 2002-03-26 2003-03-25 Hidrato estable de un antagonista de receptores muscarinicos. pc22018

Country Status (22)

Country Link
US (3) US6930188B2 (enExample)
EP (2) EP2336124B1 (enExample)
JP (2) JP2005524678A (enExample)
KR (4) KR101026283B1 (enExample)
CN (1) CN100345840C (enExample)
AR (1) AR042608A1 (enExample)
AT (1) ATE495169T1 (enExample)
AU (1) AU2003209921A1 (enExample)
BR (2) BRPI0308706B8 (enExample)
CA (1) CA2480287C (enExample)
CY (2) CY1111200T1 (enExample)
DE (1) DE60335711D1 (enExample)
DK (2) DK2336124T3 (enExample)
ES (2) ES2358644T3 (enExample)
GB (1) GB0207104D0 (enExample)
PA (1) PA8569701A1 (enExample)
PT (2) PT1490357E (enExample)
SI (2) SI2336124T1 (enExample)
SV (1) SV2003001515A (enExample)
TW (1) TW200306816A (enExample)
UY (1) UY27735A1 (enExample)
WO (1) WO2003080599A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007076159A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
WO2008144602A1 (en) * 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090018346A1 (en) * 2007-07-13 2009-01-15 Medichem, S.A. Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
JP5450387B2 (ja) 2008-04-02 2014-03-26 株式会社カネカ (s)−3−(1−シアノ−1,1−ジフェニルメチル)−ピロリジンの製造法
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2017106175A2 (en) * 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2018029140A1 (de) * 2016-08-12 2018-02-15 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von substituierten styrol-derivaten
WO2019053051A1 (en) * 2017-09-12 2019-03-21 Lts Lohmann Therapie-Systeme Ag MICRO NEEDLE IONTOPHORESIS DEVICE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
US20030191176A1 (en) 2003-10-09
PT2336124E (pt) 2012-12-12
GB0207104D0 (en) 2002-05-08
ES2358644T3 (es) 2011-05-12
ATE495169T1 (de) 2011-01-15
EP2336124B1 (en) 2012-08-29
HK1156626A1 (en) 2012-06-15
KR20110130539A (ko) 2011-12-05
BRPI0308706B8 (pt) 2021-05-25
HK1080847A1 (zh) 2006-05-04
US20080167367A1 (en) 2008-07-10
PA8569701A1 (es) 2003-12-10
JP2005524678A (ja) 2005-08-18
CA2480287A1 (en) 2003-10-02
SI1490357T1 (sl) 2011-05-31
CY1113433T1 (el) 2016-06-22
KR20100101182A (ko) 2010-09-16
AR042608A1 (es) 2005-06-29
US7696357B2 (en) 2010-04-13
US20050245597A1 (en) 2005-11-03
DK1490357T3 (da) 2011-04-04
AU2003209921A1 (en) 2003-10-08
CA2480287C (en) 2011-05-31
KR20120098888A (ko) 2012-09-05
CY1111200T1 (el) 2015-06-11
EP1490357B1 (en) 2011-01-12
BR122018000397B1 (pt) 2019-07-02
SI2336124T1 (sl) 2012-12-31
BR122018000397B8 (pt) 2021-07-27
KR101212908B1 (ko) 2012-12-14
WO2003080599A1 (en) 2003-10-02
CN100345840C (zh) 2007-10-31
JP2010195828A (ja) 2010-09-09
PT1490357E (pt) 2011-03-01
EP2336124A1 (en) 2011-06-22
CN1642945A (zh) 2005-07-20
UY27735A1 (es) 2003-10-31
BR0308706A (pt) 2005-01-04
BRPI0308706B1 (pt) 2018-07-10
EP1490357A1 (en) 2004-12-29
ES2394067T3 (es) 2013-01-16
KR101026283B1 (ko) 2011-03-31
DK2336124T3 (da) 2012-12-17
US6930188B2 (en) 2005-08-16
KR20040093477A (ko) 2004-11-05
DE60335711D1 (de) 2011-02-24
TW200306816A (en) 2003-12-01

Similar Documents

Publication Publication Date Title
SV2003001515A (es) Hidrato estable de un antagonista de receptores muscarinicos. pc22018
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
BRPI0514474A (pt) multiparticulados
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
DK1280531T3 (da) Formulering bestående af phentolaminmesylat og anvendelse heraf
JP2009543825A5 (enExample)
CY1113342T1 (el) Μεθοδος θεραπειας αθηροσκληρωσης δυσλιπιδαιμιων και σχετικων παθησεων
EA200900878A1 (ru) Пиперидиновые агонисты gpcr
DK1835924T3 (da) Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
EA200900879A1 (ru) Пиперидиновые агонисты gpcr
DE602005023197D1 (de) -muscarinrezeptors
EP2535330A3 (en) Iminopyridine derivative and use thereof
UY26627A1 (es) Antagonistas de receptores de il-8
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
DK1585546T3 (da) KIM- 1- Antagonister og Brug til at Modulere Immunsystem
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
BR0214998A (pt) Combinações farmacêuticas de agonistas do receptor da adenosina a-2a e do receptor adrenérgico beta-2
ATE375146T1 (de) Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums
UY27564A1 (es) Combinación farmacéutica.
DK1965800T3 (da) Piperidin-derivater til anvendelse i behandling af inkontinenser
Forfori et al. Metodo per la diagnosi precoce di uroperitoneo-Uromodulina
TH79776A (enExample)
Elliott Orgasmic and ejaculatory problems in clinical practice

Legal Events

Date Code Title Description
FD Lapse